Global Genes Rare Disease Stock Index Falls 7.51% After Tumultuous Week


The Global Genes Rare Disease Stock Index fell 7.51 percent for the week ending February 9, as the market engaaged in wild swings that had Wall Street speaking of a correction to the extended bull market. Though the major indices outperformed the rare disease index for the week, the GGRDSI is the only one to stay in positive territor year-to-date, albeit with just a marginal 0.56 percent on the year.

INDEX2017 Close2/2/20182/9/2018Week ChangeYTD CHANGE
GLOBAL GENES RARE DISEASE STOCK INDEX1232.321339.781239.21-7.51%0.56%
NYSE ARCA PHARMA544.93558.88528.5-5.44%-3.01%
DJIA24719.2225,520.9624,190.90-5.21%-2.14%
S&P 5002673.612,762.132,619.55-5.16%-2.02%
NASDAQ COMP6903.397,240.956,874.49-5.06%-0.42%
NASDAQ BIOTECH3356.613528.863,325.72-5.76%-0.92%


The Global Genes Rare Disease Stock Index is a price-weighted index of a representative sample of rare disease drug developers whose shares trade on U.S. exchanges. The index had a value of 1,000 on December 30, 2016. The components include Alexion Pharmaceuticals (ALXN), Amicus Therapeutics (FOLD), Audentes Therapeutics (BOLD), AveXis (AVXS), BioMarin Pharmaceutical (BMRN), bluebird Bio (BLUE), Corbus Pharmaceuticals (CRBP), Idera Pharmaceuticals (IDRA), Intercept Pharmaceuticals (ICPT), Ionis Pharmacecuticals (IONS), PTC Therapeutics (PTCT), Sarepta Therapeutics, Spark Theraeptuics (ONCE), and Ultragenyx Pharmaceutical (RARE). 

Filed Under: Business, Data Center, Global Genes

Speak Your Mind

*